Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. (ARTV) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
artv · stock forecast · 4 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 4 Wall Street analysts in the past 3 months
Buy
4 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$40.00
Consensus
$37.50
+451.5% upside
Low
$35.00
Median: $37.5 · Last Close: $6.80
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$37.50
451.5% upside
High Target
$40
488.2%
Low Target
$35
414.7%
Current Price
$6.80
as of today
Based on analyst price targets, the ARTV stock price prediction for the next 12 months ranges from $35 to $40. The consensus ARTV price forecast of $37.50 implies 451.5% upside from the current price of $6.80.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $6.46 | ↓ 5.00% |
1-day model range: $6.37–$6.55. Peak: $6.55 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ARTV · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-12 | Needham | Maintains | Buy→Buy |
| 2026-05-11 | Wedbush | Maintains | Outperform→Outperform |
| 2026-05-11 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2026-05-08 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-05-04 | Needham | Maintains | Buy→Buy |
| 2026-03-11 | Needham | Maintains | Buy→Buy |
| 2025-11-12 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-10-17 | Wedbush | Maintains | Outperform→Outperform |
| 2025-10-17 | Needham | Maintains | Buy→Buy |
| 2025-05-15 | Needham | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Artiva Biotherapeutics, Inc. (ARTV) stock. Of the recent 17 rating actions, 0 were upgrades and 0 were downgrades. 4 analysts currently cover ARTV.
Analyst Recommendation Trends
ARTV analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 5 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$0M
EPS This Year
$-2.67
EPS Next Year
$-2.91
↑ 9.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast ARTV EPS of $-2.67 for the current fiscal year, based on estimates from 4 analysts. The ARTV revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ARTV stock forecast is supported by two independent data sources: analyst consensus ratings from 4 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ARTV price target is $37.50 (+451.5% upside), with an analyst consensus of Buy.
The ARTV short-term stock prediction for tomorrow is $6.46 (-5.00%).
Artiva Biotherapeutics, Inc. trades on NASDAQ under the ticker ARTV. The ARTV stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
ARTV forecast · 8 questionsAccording to 4 Wall Street analysts, the average 12-month ARTV price target is $37.50, with a high forecast of $40.00 and a low of $35.00. The median price target is shown in the chart above when available. This implies +451.5% potential upside from the current price of $6.80.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.